Immupharma Plc

0.00 (0.0%)
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 3.01 12,655 08:32:10
Bid Price Offer Price High Price Low Price Open Price
2.91 3.07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Finance Diversified 0.12 -8.17 -2.90 - 10.04
Last Trade Time Trade Type Trade Size Trade Price Currency
09:57:08 O 11,900 3.062 GBX

Immupharma (IMM) Latest News

Immupharma (IMM) Discussions and Chat

Immupharma (IMM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Immupharma (IMM) Top Chat Posts

Top Posts
Posted at 18/5/2023 08:15 by purple11

Posts: 20,586

Price: 3.07

Strong Buy
The appetiserToday 07:58

The massive news comes June 7/8th

Posted at 14/4/2023 16:33 by johneee
finally IMM has life breathing into it and it has bottomed.

Plenty of buyers today

Looks like your prediction of 3p could both be broken and hold.

Posted at 13/4/2023 10:53 by lord loads of lolly
Best to ignore them, steering the board back to IMM where it should be.
Posted at 12/4/2023 17:18 by nobbygnome
So who is going to pay for this trial as IMM certainly don’t have sufficient funds. Presumably they are talking to partners?!?
Posted at 10/10/2022 10:12 by burtond1
Is Immupharma worth a punt ask @TMSreach "...With IMM's stock now priced less than 3p, and the approval process – though delayed – still on the tracks, is now the time to take a stake? IMM has never been cheaper. Positive news – whenever it may come – may inject new value into a share worth 7p just a couple of months ago..."
Posted at 30/9/2022 07:59 by david gruen
Lupuzor(TM) Update

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update on Lupuzor(TM), following the Company's recent announcement on 14 September 2022, that its US partner for Lupuzor(TM) (P140), Avion Pharmaceuticals ("Avion"), had received a written response from the Food and Drug Administration ("FDA") to the Type C meeting.

In summary, the FDA response earlier this month, recommended assessing the potential to use higher dosing in the next clinical program of Lupuzor(TM) in Lupus, to optimise the clinical benefit to Lupus patients and to maximise efficacy. In addition, the FDA made additional recommendations on clinical measurements, again to support Lupuzor(TM) through the regulatory process to approval.

Since then, both ImmuPharma and Avion, with their clinical and regulatory teams and advisors, have been reviewing in detail the FDA's written response and recommendations.

Further details on the next steps for Lupuzor(TM) will be communicated to the market, once finalised between ImmuPharma and Avion.

Commenting on the announcement, Tim McCarthy, CEO of ImmuPharma said:

"Following receipt of the FDA letter earlier this month, we welcome the helpful recommendations from the FDA on the next steps in the Lupuzor(TM) clinical program. We equally recognise shareholders' frustrations on what is a very complex regulatory process, which is having an impact on moving Lupuzor(TM) forward. However, we are working very closely with the clinical and regulatory teams at Avion to accommodate the FDA's recommendations and decide on the next steps. We will update the market as soon as we have further guidance to share."

Posted at 31/8/2022 09:54 by lord loads of lolly
Thanks nobby. Yes, I meant TRIAL approval. I know you feel drug dosage means it's doomed. Follow up question: based on other companies' share prices where trial approval was granted, what sort of impact would you expect this to have on IMM's share price (if trial approved). And would you anticipate an initial spike, followed by some floating back down. Or is it more likely the share price would steadily gain over the weeks following any trial approval announcement? I should really have asked you all this before jumping in again yesterday, but still interested to know your thoughts.
Posted at 04/8/2022 08:42 by mudbath
Thanks for providing some balance, supernumerary and 1bond.

So much more edifying than the trite "big plunge coming tomorrow morning" and "Tim is a disgrace!" contributions.

The IMM share price might indeed weaken further .
In this event, I would hope to benefit from taking a decent position.

Posted at 03/8/2022 17:55 by lord loads of lolly
waterloo01 - if for any reason phase 3 doesn't run, IMM is pretty much dead in the water IMHO. Its share price would tumble, Lanstead would only be paying it peanuts under the latest subscription terms & it would simply go bust. Either way, Lanstead stands to win big - or at worst lose very little. Private investors on the other hand…. nobbygnome - I don't think IMM COULD wait for the FDA's outcome. Cashburn precluded that. It's now an all or nothing gamble, based on the FDA's decision. That's far too high risk for me to invest any more dosh here, however favourable the FDA outcome may look. After all, Tim's led us down this path once before, sounding ultra confident about the company's prospects, only to see Phase 3 fail (and the share price promptly collapse). Once bitten and all that. Today's RNS is time-stamped 4.33pm (i.e. after market hours). So today's drop might pale into insignificance alongside tomorrow morning's opening? I wouldn’t be surprised to see consolidation around the 5p mark, pending the FDA’s verdict.
Posted at 12/5/2022 21:46 by mudbath
The IMM share price moves as if on a snakes and ladders board where the trades(or dice)that should determine its ascent or descent apparently having no influence.
Nevertheless, it is a great stock from which to extract a daily margin, as the MMs seem happy to part with the shares in the morning at 5.75p only to seek their return at 6p or above, after lunch.

Immupharma share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230530 10:16:40